Impact of Celiac Autoimmunity on Children with Type 1 Diabetes - 12/08/11
⁎ 
, Georgeanna J. Klingensmith, MD , Kim McFann, PhD , Marian Rewers, MD, PhD , †, Jennifer Taylor, MD , Lisa M. Emery, MSPH †, Iman Taki, BS †, Sharon Vanyi, MD , Edwin Liu, MD , ‡, Edward J. Hoffenberg, MD ‡ Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, Colorado Reprint requests: Dr Jill Simmons, 11136 Doctors’ Office Tower, 2200 Children’s Way, Nashville, TN 37232-9170.Résumé |
Objective |
Children with type 1 diabetes (T1DM) are at increased risk for celiac disease (CD); however, the benefits of screening for IgA tissue transglutaminase autoantibodies (TG), a marker for CD, are unclear.
Study design |
We compared 71 screening-identified TG+ with 63 matched TG– children with TIDM. Growth, bone density, and diabetes control measures were obtained.
Results |
The group was 10 ± 3 years of age, 46% male, with TIDM for 4 ± 3 years. Z scores for weight (0.3 ± 1 vs 0.7 ± 0.8, P = .024), body mass index (BMI) (0.3 ± 0.9 vs 0.8 ± –0.8, P = .005), and midarm circumference (0.3 ± 1.1 vs 0.6 ± 0.9, P = .031) were lower in the TG+ group. Bone mineral density and diabetes control measures were similar. When limiting the analysis to the 35 TG+ subjects with biopsy changes of CD, the BMI Z score was lower than the control group (0.4 ± 0.9 vs 0.7 ± 0.7, P = .05).
Conclusions |
In children with TIDM, screening-identified evidence of CD is associated with altered body composition, but not bone mineral density or diabetes control. Further study is needed to determine the benefit of early diagnosis and treatment of CD in TIDM children.
Le texte complet de cet article est disponible en PDF.Abbreviations : BMI, CD, GFD, HbA1c, IGF-I, IGF-BP3, LBMDA, LBMDV, NTX, PTH, T1DM, TG, TSH
Plan
| Supported by National Institutes of Health grant R01-DK50979, Autoimmunity Prevention Center grant 5U19A150864, National Institutes of Health grants DK32083, DK32493, DK63687, Autoimmunity Center of Excellence Grant U19A146374, Diabetes Endocrine Research Center P3057516, and Immune Tolerance Network Autoantibody Core Laboratory. Also supported by M01RR00069 General Clinical Research Centers Program, National Centers for Research Resources, NCRR, NIH. |
Vol 150 - N° 5
P. 461-466 - mai 2007 Retour au numéro
Article précédent
- Childhood Onset Bipolar Disorder: A Role for Early Recognition and Treatment
- Russell E. Scheffer
- Preventing a Drop in Effective Plasma Osmolality to Minimize the Likelihood of Cerebral Edema During Treatment of Children with Diabetic Ketoacidosis
- Ewout J. Hoorn, Ana P.C.P. Carlotti, Leila A.A. Costa, Beth MacMahon, Gareth Bohn, Robert Zietse, Mitchell L. Halperin, Desmond Bohn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?